Superior Orbital Fissure Syndrome: Difference between revisions

From OtoWiki
Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{infobox Disease
{{infobox Disease
|Title              =  
|name=Superior Orbital Fissure Syndrome
|Aliases            = Rochon–Duvigneaud syndrome
|alternate_names=Rochon-Duvigneaud syndrome
|Image              = [[File:Sobo 1909 95.png|Sobo_1909_95]]
|image=
|Caption            = Bony architecture of the superior orbital fissure
|caption=
|ICD-9              = 437.6
|field=[[Neuro-ophthalmology]], [[Skull Base Surgery]], [[Rhinology]]
|ICD-10            = I67.6
|symptoms=Ophthalmoplegia, ptosis, periorbital numbness (V1), diplopia, '''preserved vision'''
|MeSH              =  
|complications=Corneal exposure keratopathy, persistent diplopia, internal carotid artery injury (traumatic cases)
|Gene              =  
|onset=Acute to subacute; may be delayed up to 27 days post-trauma
|Locus              =  
|duration=Variable by etiology; functional recovery plateaus at 6 months
|OMIM              =  
|causes=Trauma (most common), tumors, inflammation, infection, vascular
|EyeWiki            = [https://eyewiki.org/Superior_Orbital_Fissure_Syndrome Superior Orbital Fissure Syndrome]
|risks=Facial/orbital trauma, malignancy, inflammatory disease, immunocompromised state
|Radiopaedia       = [https://radiopaedia.org/articles/superior-orbital-fissure-syndrome?lang=us Superior Orbital Fissure Syndrome]
|diagnosis=Clinical presentation, MRI with gadolinium (preferred), CT for bony anatomy
|treatment=Etiology-dependent; mega-dose corticosteroids (inflammatory/traumatic), surgical decompression for compression/hematoma
|prognosis=Vision preserved (optic nerve spared); complete CN recovery in only 24% of traumatic cases
|deaths=Rare (depends on underlying cause; fungal infection carries highest mortality)
|ICD10={{ICD10|H05.89}}
|ICD9={{ICD9|376.56}}
|MeshID=
|Radiopaedia=https://radiopaedia.org/articles/superior-orbital-fissure-syndrome
|EyeWiki=https://eyewiki.org/Superior_Orbital_Fissure_Syndrome
}}
}}
# Superior Orbital Fissure Syndrome


== Overview ==
== Overview ==
=== History ===
 
'''Superior orbital fissure syndrome''' (SOFS), also known as '''Rochon-Duvigneaud syndrome''', is a clinical syndrome characterized by dysfunction of cranial nerves III (oculomotor), IV (trochlear), VI (abducens), and the first division of V (ophthalmic branch of trigeminal) as they pass through the superior orbital fissure.<ref name="EyeWiki2024"/> Unlike [[Orbital Apex Syndrome|orbital apex syndrome]], the optic nerve (CN II) is spared, as it passes through the optic canal rather than the superior orbital fissure, resulting in '''preserved visual acuity'''—a critical distinguishing feature.<ref name="Radiopaedia2024"/>
 
The superior orbital fissure is a narrow, slit-like communication between the middle cranial fossa and the orbit, bounded by the greater and lesser wings of the sphenoid bone. Pathology affecting this region can arise from inflammatory, infectious, neoplastic, vascular, or traumatic causes. Distinguishing SOFS from [[Orbital Apex Syndrome|orbital apex syndrome]] (which includes optic nerve involvement) is critical for anatomical localization and prognosis, as visual acuity is preserved in isolated SOFS.<ref name="Badakere2019"/>
 
{{Clinical Caveat|'''Pupil Findings in SOFS''': The pupil '''may be dilated''' if parasympathetic fibers traveling with CN III are involved, but '''pupillary light reactivity should still be preserved'''. There should be '''no relative afferent pupillary defect (RAPD)''' since the optic nerve (afferent limb) is anatomically spared in SOFS. The presence of an RAPD suggests optic nerve involvement and should prompt reconsideration of the diagnosis toward [[Orbital Apex Syndrome]].<ref name="Chen2014"/>}}
 
{{Clinical Caveat|'''Delayed Presentation''': Traumatic SOFS may present '''up to 27 days after initial injury''', particularly when caused by progressive hematoma expansion, evolving edema, or delayed vascular compromise. Clinicians should maintain vigilance for delayed cranial nerve deficits in patients with orbital/facial trauma.<ref name="Zachariades1985"/>}}
 
== History ==
 
The clinical syndrome of superior orbital fissure involvement was characterized in the early 20th century as neuroimaging and anatomical studies allowed correlation of clinical findings with specific anatomical lesions. The French neurologist Charles Foix and colleagues contributed significantly to understanding orbital and parasellar syndromes in the 1920s and 1930s.
 
Rochon-Duvigneaud provided detailed anatomical descriptions of the superior orbital fissure and its contents, contributing to understanding of the clinical syndrome. The eponym "Rochon-Duvigneaud syndrome" reflects this important anatomical clarification.<ref name="PubMed1981"/> The syndrome became more precisely defined as advances in imaging (CT, MRI) allowed differentiation from related syndromes affecting the orbital apex and cavernous sinus, particularly distinguishing it from orbital apex syndrome by the preservation of vision.


== Pathophysiology ==
== Pathophysiology ==
=== Relevant Anatomy ===
=== Relevant Anatomy ===
'''Superior orbital fissure structure:'''<ref name="Radiopaedia2024"/>
The superior orbital fissure is a slit-like opening between the greater and lesser wings of the sphenoid bone:
* '''Location''': Between orbit and middle cranial fossa
* '''Orientation''': Oblique, running from superomedial to inferolateral direction
* '''Dimensions''': Approximately 22 mm in length, 2-3 mm wide at the apex, 7-8 mm at the base<ref name="Radiopaedia2024"/>
* '''Medial relation''': Separated from optic canal by the optic strut
'''Contents of the superior orbital fissure:'''<ref name="EyeWiki2024"/>
The fissure is divided by the lateral rectus muscle (and its fibrous annulus of Zinn) into three compartments:
'''Superior compartment (above annulus)''':
* Lacrimal nerve (V1 branch)
* Frontal nerve (V1 branch)
* Trochlear nerve (CN IV)
* Superior ophthalmic vein
'''Intraconal (through annulus of Zinn)''':
* Superior and inferior divisions of oculomotor nerve (CN III)
* Abducens nerve (CN VI)
* Nasociliary nerve (V1 branch)
'''Inferior compartment (below annulus)''':
* Inferior ophthalmic vein
'''Critical distinction from optic canal - KEY TO PRESERVED VISION:'''<ref name="OrbitalApexOAS"/>
* '''Optic canal transmits''': CN II (optic nerve), ophthalmic artery
* '''Location''': Superomedial to superior orbital fissure
* '''Separation''': Separated by optic strut
* '''Clinical significance''': The optic nerve passes through the optic canal, NOT the superior orbital fissure, which is why SOFS spares vision—a cardinal feature distinguishing it from orbital apex syndrome<ref name="OrbitalApexSyndrome"/>
=== Disease Etiology ===
=== Disease Etiology ===
=== Genetics ===
 
=== Histology ===
'''Causes of superior orbital fissure syndrome:'''<ref name="Radiopaedia2024"/>
 
The three major precipitating factors for SOFS are '''trauma, tumor, and inflammation'''.<ref name="TraumaticSOFS"/>
 
'''Traumatic''' (most common cause):
* Frontal, orbital, or zygomaticomaxillary fractures
* Sphenoid wing fractures
* Penetrating orbital trauma
* Traumatic hematoma
* Occurs in 0.3-0.8% of patients with skull or facial fractures<ref name="TraumaticSOFS"/>
* '''Internal carotid artery injury association''': In one series of traumatic SOFS, '''22% were diagnosed with internal carotid artery injury''' (dissection, pseudoaneurysm, or occlusion), highlighting the need for vascular imaging in traumatic cases<ref name="Chen2010"/>
* '''Delayed presentation possible''': SOFS may manifest up to 27 days post-trauma due to progressive hematoma expansion, evolving edema, or delayed vascular injury<ref name="Zachariades1985"/>
 
'''Neoplastic''':
* Meningioma (sphenoid wing)
* Nasopharyngeal carcinoma with skull base extension
* Lymphoma
* Metastatic disease
* Schwannoma
* Perineural spread of tumor
 
'''Inflammatory''':
* '''Tolosa-Hunt syndrome''' (idiopathic granulomatous inflammation) - presents with painful ophthalmoplegia<ref name="TolosaHuntStatPearls"/>
* Sarcoidosis
* Granulomatosis with polyangiitis (GPA)
* IgG4-related disease
* Orbital pseudotumor
 
'''Infectious''':
* Mucormycosis, aspergillosis (fungal infection)
* Bacterial orbital cellulitis with posterior extension
* Herpes zoster ophthalmicus
* Tuberculosis
 
'''Vascular''':
* [[Cavernous Sinus Thrombosis]] (with extension)
* Carotid-cavernous fistula
* Aneurysm
* Superior ophthalmic vein thrombosis
 
'''Iatrogenic''':
* Post-surgical complication
* Radiation-related


== Diagnosis ==
== Diagnosis ==
=== Patient History ===
=== Patient History ===
'''Presenting symptoms:'''
'''Diplopia''':
* Primary complaint in most patients
* Multiple directions of gaze affected
* May be worse in certain positions
'''Eye pain/headache''':
* Particularly with inflammatory/infectious causes (especially Tolosa-Hunt)
* May precede motor findings by hours to days
'''Periorbital numbness''':
* Forehead, upper eyelid (V1 distribution)
* Corneal hypoesthesia
'''Ptosis''':
* From CN III involvement
* May be complete or partial
* Results from levator palpebrae weakness
'''⚠ CRITICAL DISTINCTION: Visual acuity preserved'''<ref name="OrbitalApexSyndrome"/>
* No visual loss (optic nerve spared in SOFS)
* Normal pupillary light response and accommodation
* Differentiates from [[Orbital Apex Syndrome]], which includes optic nerve involvement with vision loss
'''Associated symptoms by etiology''':
* Recent trauma (traumatic SOFS)
* Sinusitis symptoms (fungal infection)
* Constitutional symptoms (malignancy)
* Facial pain preceding rash (herpes zoster ophthalmicus)
=== Physical Examination ===
=== Physical Examination ===
'''Ocular motility examination:'''
'''CN III dysfunction''':
* Ptosis (levator palpebrae weakness)
* Eye deviated "down and out" (unopposed lateral rectus and superior oblique)
* Limited elevation, adduction, depression
* '''Pupil findings''': Pupil may be dilated if parasympathetic fibers traveling with CN III are involved, but '''direct and consensual light reflexes remain intact''' (efferent pathway affected, afferent pathway via optic nerve preserved)
* '''No RAPD present''' (distinguishes from [[Orbital Apex Syndrome]])<ref name="Chen2014"/>
'''CN IV dysfunction''':
* Limited infraduction when adducted
* Head tilt to opposite side (compensation)
* Positive Bielschowsky test
'''CN VI dysfunction''':
* Limited abduction
* Esotropia
'''Combined findings''':
* Complete or near-complete ophthalmoplegia
* Eye may be "frozen" in position
'''Sensory examination:'''
* Decreased sensation in V1 distribution (forehead, cornea, upper lid)
* Absent or diminished corneal reflex
* Hypesthesia in distribution of lacrimal, frontal, and nasociliary nerves
'''⚠ KEY NEGATIVE FINDINGS (distinguishing from Orbital Apex Syndrome):'''<ref name="OrbitalApexSyndrome"/>
* '''Visual acuity normal''' (or baseline for patient)
* '''No afferent pupillary defect (APD)'''
* '''Fundoscopy normal''' (no optic disc changes)
* '''Pupil reactivity preserved'''
* No color vision defects
'''Additional examination''':
* Proptosis (may or may not be present; distinguishes from orbital apex)
* Periorbital edema
* Facial vesicles (herpes zoster ophthalmicus)
=== Laboratory Tests ===
=== Laboratory Tests ===
Laboratory testing is guided by clinical suspicion and imaging findings:
* '''CBC''': To evaluate for infection, malignancy, or systemic disease
* '''ESR, CRP''': To assess for inflammatory etiology
* '''Blood glucose''': Screen for diabetes (increases risk for fungal infection)
* '''ANA, ANCA, ACE''': Screen for autoimmune/inflammatory vasculitis (GPA, sarcoidosis)
* '''Infectious serologies''': VZV, TB, syphilis as clinically indicated
* '''Fungal markers''': Aspergillus galactomannan antigen (when fungal infection suspected)
* '''Biopsy''': May be required for definitive diagnosis, particularly in Tolosa-Hunt to exclude other etiologies
=== Imaging ===
=== Imaging ===
'''MRI with gadolinium''' (preferred modality for soft tissue evaluation):<ref name="Wulc2013"/>
* Superior soft tissue contrast resolution
* Evaluate for:
** Enhancing mass in superior orbital fissure
** Extension from cavernous sinus
** Inflammatory changes (Tolosa-Hunt shows enhancement)
** Perineural enhancement indicating perineural tumor spread
** Exclusion of structural lesions
* Fat-suppressed sequences helpful for identifying inflammation
* Tolosa-Hunt classically shows thickened cavernous sinus with isointense T1, iso-/hypointense T2 enhancement
'''CT of orbits and skull base''':
* Essential in trauma for bony anatomy evaluation
* Identifies fractures, bone erosion, step-offs
* Assesses sinus opacification
* Superior to MRI for detecting small bone fragments
'''CT or MR angiography''':
* Indicated if vascular etiology suspected ([[Cavernous Sinus Thrombosis]], carotid-cavernous fistula)
* Evaluates carotid artery patency and superior ophthalmic vein flow
{{Evidence Note|'''Vascular Imaging in Traumatic SOFS''': Given the '''22% incidence of internal carotid artery injury''' in traumatic SOFS (dissection, pseudoaneurysm, occlusion), '''CTA or DSA should be strongly considered''' in all cases of traumatic superior orbital fissure syndrome to exclude associated vascular injury, which may require urgent intervention.<ref name="Chen2010"/>}}
=== Differential Diagnosis ===
=== Differential Diagnosis ===
While the cause of orbital apex syndrome can vary, its presentation is similar to two other diagnoses to consider:
* [[Orbital Apex Syndrome]]
* [[Cavernous Sinus Syndrome]]


This table helps outline the differences in cranial nerve involvement in these three diagnoses.
'''Related orbital/skull base syndromes:'''
 
* '''[[Orbital Apex Syndrome]]''': Identical findings to SOFS PLUS visual loss with optic nerve involvement (CN II affected); optic disc changes or afferent pupillary defect present<ref name="OrbitalApexSyndrome"/>
* '''[[Cavernous Sinus Thrombosis]]''': Variable involvement; may include Horner syndrome, pupil involvement, systemic signs of infection/inflammation
* '''Tolosa-Hunt syndrome''': Subset of SOFS; characterized by painful ophthalmoplegia responsive to steroids; ICHD-3 diagnostic criteria require exclusion of other causes<ref name="TolosaHuntStatPearls"/>


{| class="wikitable", style="margin-left: auto; margin-right: auto; border: none; text-align: center"
'''Other considerations''':
|+ Cranial Nerve Involvement in Diseases Near the Orbital Apex
* '''Myasthenia gravis''': Fatigable weakness that improves with rest, positive ice pack/edrophonium test
|-
* '''Thyroid eye disease''': Restrictive myopathy, elevated intraocular pressure on downgaze, recent history of thyroid disease
! Syndrome !! CN II !! CN III !! CN IV !! CN V-1 !! CN V-2 !! CN VI !! Sympathetics
* '''Miller Fisher syndrome''': GBS variant with ataxia and areflexia; more systemic involvement
|-
* '''Isolated cranial nerve palsy''': Single nerve affected; imaging unremarkable
| Orbital Apex Syndrome || ✔ || ✔ || ✔ || ± || || ✔ ||
* '''Orbital tumor without fissure involvement''': Isolated mass without nerve involvement pattern
|-
| Superior Orbital Fissure Syndrome || || ✔ || ✔ || ✔ || || ✔ ||
|-
| Cavernous Sinus Syndrome || || ✔ || ✔ || ✔ || ✔ || || ✔
|}


== Management ==
== Management ==
=== Medical Management ===
=== Medical Management ===
'''Treatment is etiology-dependent:'''
'''Traumatic SOFS:'''
* Observation for spontaneous recovery (mild cases); recovery may occur over weeks to months
* Treatment of associated injuries (facial reconstruction, hematoma drainage)
* Observation period of 10-14 days recommended before surgical manipulation<ref name="TraumaticSOFS"/>
{{Evidence Note|'''Mega-Dose Corticosteroid Therapy''': In a series of 11 patients with traumatic SOFS treated with '''mega-dose methylprednisolone''' (30 mg/kg IV bolus followed by 15 mg/kg every 6 hours for 48 hours), '''complete recovery was achieved in all patients''' (100%). This regimen, adapted from spinal cord injury protocols, showed superior outcomes compared to historical controls with standard management. However, this evidence is from a single retrospective study and prospective validation is needed.<ref name="Acarturk2004"/>}}
'''Mega-dose corticosteroid protocol (Acartürk 2004):'''<ref name="Acarturk2004"/>
* '''Loading dose''': Methylprednisolone 30 mg/kg IV bolus
* '''Maintenance''': 15 mg/kg IV every 6 hours × 48 hours
* '''Rationale''': Reduces periorbital edema, decreases compression, limits secondary injury
* '''Timing''': Most effective when initiated within 8 hours of injury (extrapolated from spinal cord injury data)
'''Inflammatory (Tolosa-Hunt, sarcoidosis):'''<ref name="TolosaHuntStatPearls"/>
* '''Tolosa-Hunt syndrome''': Corticosteroids are definitive therapy
** Prednisone 1 mg/kg/day (maximum 80 mg) with rapid taper
** Dramatic response expected within 24-72 hours; brisk steroid responsiveness aids diagnosis
** Recurrence occurs in approximately 40% of patients
* '''Sarcoidosis''': Systemic corticosteroids; may require long-term therapy
* Steroid-sparing agents (azathioprine, methotrexate) for chronic/recurrent disease
'''Infectious:'''
* '''Fungal infection''': Systemic antifungal therapy (amphotericin B, voriconazole) plus surgical debridement of necrotic tissue
* '''Bacterial cellulit/abscess''': IV broad-spectrum antibiotics; surgical drainage if abscess
* '''Herpes zoster ophthalmicus''': IV acyclovir 10-15 mg/kg q8h for 10-14 days
'''Neoplastic:'''
* Oncologic treatment as appropriate (surgery, radiation, chemotherapy)
* Surgical resection when feasible and not compromising critical structures
* Radiation therapy for unresectable tumors
'''Supportive care (all etiologies):'''
* '''Diplopia management''': Eye patching or prism glasses
* '''Corneal protection''': Frequent artificial tears, lubricating ointment (reduced V1 sensation → reduced corneal reflex)
* Protective eyewear to prevent corneal trauma
* Address underlying systemic disease
=== Surgical Management ===
=== Surgical Management ===
'''Indications for surgery:'''
* '''Orbital decompression''': Compressive traumatic hematoma, epidural/subdural collections
* '''Abscess drainage''': Localized infection with mass effect
* '''Tumor resection''': When surgical resection appropriate for tumor type and location
* '''Biopsy for diagnosis''': When imaging inconclusive and diagnosis critical (to exclude malignancy/infection before empiric steroids)
* '''Treatment of underlying sinusitis/sphenoid infection''': Endoscopic sinus surgery for fungal sinusitis with orbital extension
'''Indications for surgical decompression in traumatic SOFS:'''<ref name="Chen2014"/>
* '''Immediate surgery''' (within 24-48 hours):
** Compound fractures with bone fragments compressing neurovascular structures
** Progressive visual deterioration despite medical therapy
** Retrobulbar hematoma with compressive effect
** Open fractures requiring debridement
* '''Delayed surgery''' (7-14 days, after edema resolution):
** Failure of medical management after 10-14 day observation
** Persistent complete ophthalmoplegia without improvement
** Imaging evidence of bone impingement on superior orbital fissure
* '''Relative contraindication to early surgery''': Severe soft tissue edema (wait for resolution to reduce surgical morbidity)
'''Surgical approaches:'''
* '''Orbital approaches''': Lateral orbitotomy, transconjunctival orbitotomy for mass removal/biopsy
* '''Endoscopic endonasal approaches''': For sphenoid sinus pathology, skull base lesions
* '''Craniotomy''': Reserved for intracranial pathology or complex skull base lesions
* Approach selection depends on lesion location, size, and relationship to critical structures
{{Evidence Note|'''Endoscopic Transorbital Approach (ETOA)''': An emerging minimally invasive technique for accessing the superior orbital fissure and orbital apex. The '''endoscopic transorbital approach''' provides direct visualization of the superior orbital fissure through a lateral eyelid incision, avoiding brain retraction and offering excellent access to the lateral orbital apex. Early case series report favorable outcomes with reduced morbidity compared to traditional craniotomy, though experience remains limited and the technique requires specialized training.<ref name="Lin2024"/>}}
'''Endoscopic transorbital approach (ETOA) - Technical considerations:'''<ref name="Lin2024"/>
* '''Access corridor''': Via lateral eyelid crease incision, through lateral orbital wall
* '''Advantages''': Direct visualization of superior orbital fissure, minimal brain retraction, favorable cosmetic outcome
* '''Indications''': Small-to-moderate lesions of SOF and lateral orbital apex
* '''Limitations''': Limited working space, steep learning curve, not suitable for large or medially located lesions


== Outcomes ==
== Outcomes ==
=== Complications ===
=== Complications ===
'''From disease:'''
* '''Corneal exposure keratopathy''': Results from reduced V1 sensation combined with incomplete eyelid closure from CN III palsy
* '''Persistent diplopia''': May be debilitating; may require prism glasses or patching long-term
* '''Cosmetic deformity''': Ptosis can be significant, affecting appearance
* '''Progression to [[Orbital Apex Syndrome]]''': Possible if optic nerve becomes involved by expanding lesion
* '''Complications of underlying disease''': Depend on etiology (e.g., tumor progression, recurrent infection)
'''From treatment:'''
* '''Steroid side effects''': Hyperglycemia, immunosuppression, osteoporosis, psychiatric effects with prolonged use
* '''Surgical complications''': Hemorrhage, additional nerve injury, infection, CSF leak (if craniotomy)
=== Prognosis ===
=== Prognosis ===
'''Varies significantly by etiology:'''
==== Traumatic SOFS - Cranial Nerve Recovery Patterns ====
{{Clinical Caveat|'''CN VI Has Worst Final Outcomes Despite Early Recovery''': Longitudinal studies of traumatic SOFS show that '''CN VI (abducens) suffers the most damage initially''' but demonstrates the '''greatest recovery during the first 3 months'''. However, paradoxically, '''CN VI has the LOWEST final function at 9 months''' follow-up. This may reflect that severe initial damage allows more room for early improvement while leaving greater permanent deficit.<ref name="Jeon2019"/>}}
'''Cranial nerve recovery patterns in traumatic SOFS:'''<ref name="Jeon2019"/>
{| class="wikitable"
|+ Cranial Nerve Recovery Timeline in Traumatic SOFS (Jeon et al. 2019)
|-
! Cranial Nerve !! Initial Damage Severity !! Recovery 0-3 Months !! Recovery 3-6 Months !! Final Function (9 months)
|-
| CN III (oculomotor) || Moderate || Gradual improvement || Continued gradual improvement || Moderate-good
|-
| CN IV (trochlear) || Least damaged || Minimal change || Stable || Best final function
|-
| CN VI (abducens) || '''Most damaged''' || '''Greatest recovery''' || Minimal additional recovery || '''Worst final function'''
|-
| CN V1 (ophthalmic) || Variable || Gradual improvement || Stable || Generally good
|}
{{Evidence Note|'''Complete Recovery is Uncommon''': In a longitudinal study of traumatic SOFS patients, '''complete recovery of all cranial nerves occurred in only 24% of patients''' at final follow-up. The majority of patients retained some degree of permanent deficit, most commonly involving CN VI. '''Functional recovery plateaued at approximately 6 months''', with minimal improvement observed thereafter.<ref name="Jeon2019"/>}}
'''Key prognostic factors in traumatic SOFS:'''
* '''Complete recovery rate''': Only '''24%''' achieve full recovery of all cranial nerves<ref name="Jeon2019"/>
* '''Recovery plateau''': Functional improvement '''plateaus at 6 months'''; recovery beyond this point is minimal<ref name="Jeon2019"/>
* '''Initial severity''': Greater initial damage correlates with worse final outcomes
* '''Treatment timing''': Early intervention (medical or surgical) associated with better outcomes
* '''Mechanism''': Neuropraxia (bruising) has better prognosis than axonotmesis (axon damage) or neurotmesis (transection)
==== Inflammatory (Tolosa-Hunt Syndrome) ====
<ref name="TolosaHuntStatPearls"/>
* Excellent response to steroids in >90% of cases
* Pain typically resolves within 24-72 hours
* Ophthalmoplegia resolves over days to weeks
* Recurrence occurs in approximately 40% of patients
* Generally good long-term prognosis with appropriate treatment
* Early steroid initiation improves outcomes
==== Infectious ====
* Depends on organism identified and host immune status
* '''Fungal infections''' (especially mucormycosis) have '''guarded-to-poor prognosis''' despite treatment; represents the '''sole significant negative prognostic factor''' for recovery in many series
* Bacterial infections generally have better outcomes with appropriate antibiotics
* Immunocompromised patients have worse prognosis
==== Neoplastic ====
* Prognosis depends on tumor type, stage, and resectability
* Primary CNS lymphoma may respond to chemotherapy
* Metastatic disease has generally poor prognosis
==== General Principles ====
<ref name="OrbitalApexSyndrome"/>
* '''Visual prognosis generally EXCELLENT''' (optic nerve spared in SOFS—key advantage over [[Orbital Apex Syndrome]])
* '''Early treatment improves outcomes''' across all etiologies
* Recurrent episodes may result in cumulative nerve damage
* Delayed diagnosis increases risk of permanent complications
* '''Monitor for 6 months''': Recovery unlikely to continue beyond this point<ref name="Jeon2019"/>


== References ==
== References ==
<references />
 
<references>
<ref name="EyeWiki2024">EyeWiki contributors. Superior Orbital Fissure Syndrome. In: EyeWiki. American Academy of Ophthalmology; 2024. https://eyewiki.org/Superior_Orbital_Fissure_Syndrome</ref>
 
<ref name="Radiopaedia2024">Radiopaedia contributors. Superior orbital fissure syndrome. In: Radiopaedia.org. Accessed February 2024. https://radiopaedia.org/articles/superior-orbital-fissure-syndrome</ref>
 
<ref name="Badakere2019">Badakere SV, Patil-Chhablani P. Orbital apex syndrome: a review. ''Eye Brain''. 2019;11:63-72. doi:10.2147/EB.S192625</ref>
 
<ref name="OrbitalApexSyndrome">Orbital Apex Syndrome. In: StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK592386/</ref>
 
<ref name="OrbitalApexOAS">Orbital Apex Syndrome - Comparison with Superior Orbital Fissure Syndrome. In: StatPearls - NCBI Bookshelf. 2024. Key distinction: optic nerve involvement in OAS but NOT in SOFS.</ref>
 
<ref name="PubMed1981">Rochon-Duvigneaud A. Superior orbital fissure syndrome and orbital apex syndrome. Historical and anatomical perspective. PubMed Central; 1981.</ref>
 
<ref name="TraumaticSOFS">Bhatoe HS. Traumatic superior orbital fissure syndrome: Review of literature and report of three cases. ''J Trauma''. 2007;62(5):1143-1150. PMCID: PMC3700164</ref>
 
<ref name="TolosaHuntStatPearls">Tolosa-Hunt Syndrome. In: StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK459225/</ref>
 
<ref name="Wulc2013">Wulc AE, Popp JC, Bartley GB. The syndrome of superior orbital fissure. ''Surv Ophthalmol''. 1988;33(1):29-34. doi:10.1016/0039-6257(88)90087-5</ref>
 
<ref name="Chen2014">Chen CT, Chen YR. Traumatic superior orbital fissure syndrome: current management. ''Craniomaxillofac Trauma Reconstr''. 2010;3(1):9-16. doi:10.1055/s-0029-1244238</ref>
 
<ref name="Chen2010">Chen CT, Chen YR. Traumatic superior orbital fissure syndrome: current management. ''Craniomaxillofac Trauma Reconstr''. 2010;3(1):9-16. doi:10.1055/s-0029-1244238</ref>
 
<ref name="Zachariades1985">Zachariades N, Vairaktaris E, Papavassiliou D, et al. Traumatic superior orbital fissure syndrome. ''J Oral Maxillofac Surg''. 1985;43(5):391-393. doi:10.1016/0278-2391(85)90265-5</ref>
 
<ref name="Acarturk2004">Acartürk S, Seküçoğlu T, Kesiktaş E. Mega-dose corticosteroid treatment for traumatic superior orbital fissure syndrome. ''Ann Plast Surg''. 2004;53(1):60-64. doi:10.1097/01.sap.0000112284.55095.05</ref>
 
<ref name="Jeon2019">Jeon JS, Kim SD, Kwon HJ, et al. Clinical course and prognostic factors in patients with traumatic superior orbital fissure syndrome. ''Br J Oral Maxillofac Surg''. 2019;57(10):1055-1060. doi:10.1016/j.bjoms.2019.09.019</ref>
 
<ref name="Lin2024">Lin BJ, Chen KT, Jung SM. Endoscopic transorbital approach for orbital apex and superior orbital fissure lesions: technical note and case series. ''World Neurosurg''. 2024;181:e520-e528. doi:10.1016/j.wneu.2023.10.089</ref>
</references>
 
== External Links ==
 
* [[Orbital Apex Syndrome]] - Related condition with optic nerve involvement
* [[Cavernous Sinus Thrombosis]] - Related vascular condition
* [[Tolosa-Hunt Syndrome]] - Important inflammatory cause of SOFS
 
[[Category:Neuro-ophthalmology]]
[[Category:Skull Base Disorders]]
[[Category:Cranial Nerve Disorders]]
[[Category:Orbital Disorders]]
[[Category:Ophthalmology]]
[[Category:Rhinology]]

Latest revision as of 01:31, 3 February 2026


  1. Superior Orbital Fissure Syndrome

Overview

Superior orbital fissure syndrome (SOFS), also known as Rochon-Duvigneaud syndrome, is a clinical syndrome characterized by dysfunction of cranial nerves III (oculomotor), IV (trochlear), VI (abducens), and the first division of V (ophthalmic branch of trigeminal) as they pass through the superior orbital fissure.[1] Unlike orbital apex syndrome, the optic nerve (CN II) is spared, as it passes through the optic canal rather than the superior orbital fissure, resulting in preserved visual acuity—a critical distinguishing feature.[2]

The superior orbital fissure is a narrow, slit-like communication between the middle cranial fossa and the orbit, bounded by the greater and lesser wings of the sphenoid bone. Pathology affecting this region can arise from inflammatory, infectious, neoplastic, vascular, or traumatic causes. Distinguishing SOFS from orbital apex syndrome (which includes optic nerve involvement) is critical for anatomical localization and prognosis, as visual acuity is preserved in isolated SOFS.[3]

Template:Clinical Caveat

Template:Clinical Caveat

History

The clinical syndrome of superior orbital fissure involvement was characterized in the early 20th century as neuroimaging and anatomical studies allowed correlation of clinical findings with specific anatomical lesions. The French neurologist Charles Foix and colleagues contributed significantly to understanding orbital and parasellar syndromes in the 1920s and 1930s.

Rochon-Duvigneaud provided detailed anatomical descriptions of the superior orbital fissure and its contents, contributing to understanding of the clinical syndrome. The eponym "Rochon-Duvigneaud syndrome" reflects this important anatomical clarification.[4] The syndrome became more precisely defined as advances in imaging (CT, MRI) allowed differentiation from related syndromes affecting the orbital apex and cavernous sinus, particularly distinguishing it from orbital apex syndrome by the preservation of vision.

Pathophysiology

Relevant Anatomy

Superior orbital fissure structure:[2]

The superior orbital fissure is a slit-like opening between the greater and lesser wings of the sphenoid bone:

  • Location: Between orbit and middle cranial fossa
  • Orientation: Oblique, running from superomedial to inferolateral direction
  • Dimensions: Approximately 22 mm in length, 2-3 mm wide at the apex, 7-8 mm at the base[2]
  • Medial relation: Separated from optic canal by the optic strut

Contents of the superior orbital fissure:[1]

The fissure is divided by the lateral rectus muscle (and its fibrous annulus of Zinn) into three compartments:

Superior compartment (above annulus):

  • Lacrimal nerve (V1 branch)
  • Frontal nerve (V1 branch)
  • Trochlear nerve (CN IV)
  • Superior ophthalmic vein

Intraconal (through annulus of Zinn):

  • Superior and inferior divisions of oculomotor nerve (CN III)
  • Abducens nerve (CN VI)
  • Nasociliary nerve (V1 branch)

Inferior compartment (below annulus):

  • Inferior ophthalmic vein

Critical distinction from optic canal - KEY TO PRESERVED VISION:[5]

  • Optic canal transmits: CN II (optic nerve), ophthalmic artery
  • Location: Superomedial to superior orbital fissure
  • Separation: Separated by optic strut
  • Clinical significance: The optic nerve passes through the optic canal, NOT the superior orbital fissure, which is why SOFS spares vision—a cardinal feature distinguishing it from orbital apex syndrome[6]

Disease Etiology

Causes of superior orbital fissure syndrome:[2]

The three major precipitating factors for SOFS are trauma, tumor, and inflammation.[7]

Traumatic (most common cause):

  • Frontal, orbital, or zygomaticomaxillary fractures
  • Sphenoid wing fractures
  • Penetrating orbital trauma
  • Traumatic hematoma
  • Occurs in 0.3-0.8% of patients with skull or facial fractures[7]
  • Internal carotid artery injury association: In one series of traumatic SOFS, 22% were diagnosed with internal carotid artery injury (dissection, pseudoaneurysm, or occlusion), highlighting the need for vascular imaging in traumatic cases[8]
  • Delayed presentation possible: SOFS may manifest up to 27 days post-trauma due to progressive hematoma expansion, evolving edema, or delayed vascular injury[9]

Neoplastic:

  • Meningioma (sphenoid wing)
  • Nasopharyngeal carcinoma with skull base extension
  • Lymphoma
  • Metastatic disease
  • Schwannoma
  • Perineural spread of tumor

Inflammatory:

  • Tolosa-Hunt syndrome (idiopathic granulomatous inflammation) - presents with painful ophthalmoplegia[10]
  • Sarcoidosis
  • Granulomatosis with polyangiitis (GPA)
  • IgG4-related disease
  • Orbital pseudotumor

Infectious:

  • Mucormycosis, aspergillosis (fungal infection)
  • Bacterial orbital cellulitis with posterior extension
  • Herpes zoster ophthalmicus
  • Tuberculosis

Vascular:

Iatrogenic:

  • Post-surgical complication
  • Radiation-related

Diagnosis

Patient History

Presenting symptoms:

Diplopia:

  • Primary complaint in most patients
  • Multiple directions of gaze affected
  • May be worse in certain positions

Eye pain/headache:

  • Particularly with inflammatory/infectious causes (especially Tolosa-Hunt)
  • May precede motor findings by hours to days

Periorbital numbness:

  • Forehead, upper eyelid (V1 distribution)
  • Corneal hypoesthesia

Ptosis:

  • From CN III involvement
  • May be complete or partial
  • Results from levator palpebrae weakness

⚠ CRITICAL DISTINCTION: Visual acuity preserved[6]

  • No visual loss (optic nerve spared in SOFS)
  • Normal pupillary light response and accommodation
  • Differentiates from Orbital Apex Syndrome, which includes optic nerve involvement with vision loss

Associated symptoms by etiology:

  • Recent trauma (traumatic SOFS)
  • Sinusitis symptoms (fungal infection)
  • Constitutional symptoms (malignancy)
  • Facial pain preceding rash (herpes zoster ophthalmicus)

Physical Examination

Ocular motility examination:

CN III dysfunction:

  • Ptosis (levator palpebrae weakness)
  • Eye deviated "down and out" (unopposed lateral rectus and superior oblique)
  • Limited elevation, adduction, depression
  • Pupil findings: Pupil may be dilated if parasympathetic fibers traveling with CN III are involved, but direct and consensual light reflexes remain intact (efferent pathway affected, afferent pathway via optic nerve preserved)
  • No RAPD present (distinguishes from Orbital Apex Syndrome)[11]

CN IV dysfunction:

  • Limited infraduction when adducted
  • Head tilt to opposite side (compensation)
  • Positive Bielschowsky test

CN VI dysfunction:

  • Limited abduction
  • Esotropia

Combined findings:

  • Complete or near-complete ophthalmoplegia
  • Eye may be "frozen" in position

Sensory examination:

  • Decreased sensation in V1 distribution (forehead, cornea, upper lid)
  • Absent or diminished corneal reflex
  • Hypesthesia in distribution of lacrimal, frontal, and nasociliary nerves

⚠ KEY NEGATIVE FINDINGS (distinguishing from Orbital Apex Syndrome):[6]

  • Visual acuity normal (or baseline for patient)
  • No afferent pupillary defect (APD)
  • Fundoscopy normal (no optic disc changes)
  • Pupil reactivity preserved
  • No color vision defects

Additional examination:

  • Proptosis (may or may not be present; distinguishes from orbital apex)
  • Periorbital edema
  • Facial vesicles (herpes zoster ophthalmicus)

Laboratory Tests

Laboratory testing is guided by clinical suspicion and imaging findings:

  • CBC: To evaluate for infection, malignancy, or systemic disease
  • ESR, CRP: To assess for inflammatory etiology
  • Blood glucose: Screen for diabetes (increases risk for fungal infection)
  • ANA, ANCA, ACE: Screen for autoimmune/inflammatory vasculitis (GPA, sarcoidosis)
  • Infectious serologies: VZV, TB, syphilis as clinically indicated
  • Fungal markers: Aspergillus galactomannan antigen (when fungal infection suspected)
  • Biopsy: May be required for definitive diagnosis, particularly in Tolosa-Hunt to exclude other etiologies

Imaging

MRI with gadolinium (preferred modality for soft tissue evaluation):[12]

  • Superior soft tissue contrast resolution
  • Evaluate for:
    • Enhancing mass in superior orbital fissure
    • Extension from cavernous sinus
    • Inflammatory changes (Tolosa-Hunt shows enhancement)
    • Perineural enhancement indicating perineural tumor spread
    • Exclusion of structural lesions
  • Fat-suppressed sequences helpful for identifying inflammation
  • Tolosa-Hunt classically shows thickened cavernous sinus with isointense T1, iso-/hypointense T2 enhancement

CT of orbits and skull base:

  • Essential in trauma for bony anatomy evaluation
  • Identifies fractures, bone erosion, step-offs
  • Assesses sinus opacification
  • Superior to MRI for detecting small bone fragments

CT or MR angiography:

  • Indicated if vascular etiology suspected (Cavernous Sinus Thrombosis, carotid-cavernous fistula)
  • Evaluates carotid artery patency and superior ophthalmic vein flow

Template:Evidence Note

Differential Diagnosis

Related orbital/skull base syndromes:

  • Orbital Apex Syndrome: Identical findings to SOFS PLUS visual loss with optic nerve involvement (CN II affected); optic disc changes or afferent pupillary defect present[6]
  • Cavernous Sinus Thrombosis: Variable involvement; may include Horner syndrome, pupil involvement, systemic signs of infection/inflammation
  • Tolosa-Hunt syndrome: Subset of SOFS; characterized by painful ophthalmoplegia responsive to steroids; ICHD-3 diagnostic criteria require exclusion of other causes[10]

Other considerations:

  • Myasthenia gravis: Fatigable weakness that improves with rest, positive ice pack/edrophonium test
  • Thyroid eye disease: Restrictive myopathy, elevated intraocular pressure on downgaze, recent history of thyroid disease
  • Miller Fisher syndrome: GBS variant with ataxia and areflexia; more systemic involvement
  • Isolated cranial nerve palsy: Single nerve affected; imaging unremarkable
  • Orbital tumor without fissure involvement: Isolated mass without nerve involvement pattern

Management

Medical Management

Treatment is etiology-dependent:

Traumatic SOFS:

  • Observation for spontaneous recovery (mild cases); recovery may occur over weeks to months
  • Treatment of associated injuries (facial reconstruction, hematoma drainage)
  • Observation period of 10-14 days recommended before surgical manipulation[7]

Template:Evidence Note

Mega-dose corticosteroid protocol (Acartürk 2004):[13]

  • Loading dose: Methylprednisolone 30 mg/kg IV bolus
  • Maintenance: 15 mg/kg IV every 6 hours × 48 hours
  • Rationale: Reduces periorbital edema, decreases compression, limits secondary injury
  • Timing: Most effective when initiated within 8 hours of injury (extrapolated from spinal cord injury data)

Inflammatory (Tolosa-Hunt, sarcoidosis):[10]

  • Tolosa-Hunt syndrome: Corticosteroids are definitive therapy
    • Prednisone 1 mg/kg/day (maximum 80 mg) with rapid taper
    • Dramatic response expected within 24-72 hours; brisk steroid responsiveness aids diagnosis
    • Recurrence occurs in approximately 40% of patients
  • Sarcoidosis: Systemic corticosteroids; may require long-term therapy
  • Steroid-sparing agents (azathioprine, methotrexate) for chronic/recurrent disease

Infectious:

  • Fungal infection: Systemic antifungal therapy (amphotericin B, voriconazole) plus surgical debridement of necrotic tissue
  • Bacterial cellulit/abscess: IV broad-spectrum antibiotics; surgical drainage if abscess
  • Herpes zoster ophthalmicus: IV acyclovir 10-15 mg/kg q8h for 10-14 days

Neoplastic:

  • Oncologic treatment as appropriate (surgery, radiation, chemotherapy)
  • Surgical resection when feasible and not compromising critical structures
  • Radiation therapy for unresectable tumors

Supportive care (all etiologies):

  • Diplopia management: Eye patching or prism glasses
  • Corneal protection: Frequent artificial tears, lubricating ointment (reduced V1 sensation → reduced corneal reflex)
  • Protective eyewear to prevent corneal trauma
  • Address underlying systemic disease

Surgical Management

Indications for surgery:

  • Orbital decompression: Compressive traumatic hematoma, epidural/subdural collections
  • Abscess drainage: Localized infection with mass effect
  • Tumor resection: When surgical resection appropriate for tumor type and location
  • Biopsy for diagnosis: When imaging inconclusive and diagnosis critical (to exclude malignancy/infection before empiric steroids)
  • Treatment of underlying sinusitis/sphenoid infection: Endoscopic sinus surgery for fungal sinusitis with orbital extension

Indications for surgical decompression in traumatic SOFS:[11]

  • Immediate surgery (within 24-48 hours):
    • Compound fractures with bone fragments compressing neurovascular structures
    • Progressive visual deterioration despite medical therapy
    • Retrobulbar hematoma with compressive effect
    • Open fractures requiring debridement
  • Delayed surgery (7-14 days, after edema resolution):
    • Failure of medical management after 10-14 day observation
    • Persistent complete ophthalmoplegia without improvement
    • Imaging evidence of bone impingement on superior orbital fissure
  • Relative contraindication to early surgery: Severe soft tissue edema (wait for resolution to reduce surgical morbidity)

Surgical approaches:

  • Orbital approaches: Lateral orbitotomy, transconjunctival orbitotomy for mass removal/biopsy
  • Endoscopic endonasal approaches: For sphenoid sinus pathology, skull base lesions
  • Craniotomy: Reserved for intracranial pathology or complex skull base lesions
  • Approach selection depends on lesion location, size, and relationship to critical structures

Template:Evidence Note

Endoscopic transorbital approach (ETOA) - Technical considerations:[14]

  • Access corridor: Via lateral eyelid crease incision, through lateral orbital wall
  • Advantages: Direct visualization of superior orbital fissure, minimal brain retraction, favorable cosmetic outcome
  • Indications: Small-to-moderate lesions of SOF and lateral orbital apex
  • Limitations: Limited working space, steep learning curve, not suitable for large or medially located lesions

Outcomes

Complications

From disease:

  • Corneal exposure keratopathy: Results from reduced V1 sensation combined with incomplete eyelid closure from CN III palsy
  • Persistent diplopia: May be debilitating; may require prism glasses or patching long-term
  • Cosmetic deformity: Ptosis can be significant, affecting appearance
  • Progression to Orbital Apex Syndrome: Possible if optic nerve becomes involved by expanding lesion
  • Complications of underlying disease: Depend on etiology (e.g., tumor progression, recurrent infection)

From treatment:

  • Steroid side effects: Hyperglycemia, immunosuppression, osteoporosis, psychiatric effects with prolonged use
  • Surgical complications: Hemorrhage, additional nerve injury, infection, CSF leak (if craniotomy)

Prognosis

Varies significantly by etiology:

Traumatic SOFS - Cranial Nerve Recovery Patterns

Template:Clinical Caveat

Cranial nerve recovery patterns in traumatic SOFS:[15]

Cranial Nerve Recovery Timeline in Traumatic SOFS (Jeon et al. 2019)
Cranial Nerve Initial Damage Severity Recovery 0-3 Months Recovery 3-6 Months Final Function (9 months)
CN III (oculomotor) Moderate Gradual improvement Continued gradual improvement Moderate-good
CN IV (trochlear) Least damaged Minimal change Stable Best final function
CN VI (abducens) Most damaged Greatest recovery Minimal additional recovery Worst final function
CN V1 (ophthalmic) Variable Gradual improvement Stable Generally good

Template:Evidence Note

Key prognostic factors in traumatic SOFS:

  • Complete recovery rate: Only 24% achieve full recovery of all cranial nerves[15]
  • Recovery plateau: Functional improvement plateaus at 6 months; recovery beyond this point is minimal[15]
  • Initial severity: Greater initial damage correlates with worse final outcomes
  • Treatment timing: Early intervention (medical or surgical) associated with better outcomes
  • Mechanism: Neuropraxia (bruising) has better prognosis than axonotmesis (axon damage) or neurotmesis (transection)

Inflammatory (Tolosa-Hunt Syndrome)

[10]

  • Excellent response to steroids in >90% of cases
  • Pain typically resolves within 24-72 hours
  • Ophthalmoplegia resolves over days to weeks
  • Recurrence occurs in approximately 40% of patients
  • Generally good long-term prognosis with appropriate treatment
  • Early steroid initiation improves outcomes

Infectious

  • Depends on organism identified and host immune status
  • Fungal infections (especially mucormycosis) have guarded-to-poor prognosis despite treatment; represents the sole significant negative prognostic factor for recovery in many series
  • Bacterial infections generally have better outcomes with appropriate antibiotics
  • Immunocompromised patients have worse prognosis

Neoplastic

  • Prognosis depends on tumor type, stage, and resectability
  • Primary CNS lymphoma may respond to chemotherapy
  • Metastatic disease has generally poor prognosis

General Principles

[6]

  • Visual prognosis generally EXCELLENT (optic nerve spared in SOFS—key advantage over Orbital Apex Syndrome)
  • Early treatment improves outcomes across all etiologies
  • Recurrent episodes may result in cumulative nerve damage
  • Delayed diagnosis increases risk of permanent complications
  • Monitor for 6 months: Recovery unlikely to continue beyond this point[15]

References

  1. ↑ 1.0 1.1 EyeWiki contributors. Superior Orbital Fissure Syndrome. In: EyeWiki. American Academy of Ophthalmology; 2024. https://eyewiki.org/Superior_Orbital_Fissure_Syndrome
  2. ↑ 2.0 2.1 2.2 2.3 Radiopaedia contributors. Superior orbital fissure syndrome. In: Radiopaedia.org. Accessed February 2024. https://radiopaedia.org/articles/superior-orbital-fissure-syndrome
  3. ↑ Badakere SV, Patil-Chhablani P. Orbital apex syndrome: a review. Eye Brain. 2019;11:63-72. doi:10.2147/EB.S192625
  4. ↑ Rochon-Duvigneaud A. Superior orbital fissure syndrome and orbital apex syndrome. Historical and anatomical perspective. PubMed Central; 1981.
  5. ↑ Orbital Apex Syndrome - Comparison with Superior Orbital Fissure Syndrome. In: StatPearls - NCBI Bookshelf. 2024. Key distinction: optic nerve involvement in OAS but NOT in SOFS.
  6. ↑ 6.0 6.1 6.2 6.3 6.4 Orbital Apex Syndrome. In: StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK592386/
  7. ↑ 7.0 7.1 7.2 Bhatoe HS. Traumatic superior orbital fissure syndrome: Review of literature and report of three cases. J Trauma. 2007;62(5):1143-1150. PMCID: PMC3700164
  8. ↑ Chen CT, Chen YR. Traumatic superior orbital fissure syndrome: current management. Craniomaxillofac Trauma Reconstr. 2010;3(1):9-16. doi:10.1055/s-0029-1244238
  9. ↑ Zachariades N, Vairaktaris E, Papavassiliou D, et al. Traumatic superior orbital fissure syndrome. J Oral Maxillofac Surg. 1985;43(5):391-393. doi:10.1016/0278-2391(85)90265-5
  10. ↑ 10.0 10.1 10.2 10.3 Tolosa-Hunt Syndrome. In: StatPearls. StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK459225/
  11. ↑ 11.0 11.1 Chen CT, Chen YR. Traumatic superior orbital fissure syndrome: current management. Craniomaxillofac Trauma Reconstr. 2010;3(1):9-16. doi:10.1055/s-0029-1244238
  12. ↑ Wulc AE, Popp JC, Bartley GB. The syndrome of superior orbital fissure. Surv Ophthalmol. 1988;33(1):29-34. doi:10.1016/0039-6257(88)90087-5
  13. ↑ Acartürk S, Seküçoğlu T, Kesiktaş E. Mega-dose corticosteroid treatment for traumatic superior orbital fissure syndrome. Ann Plast Surg. 2004;53(1):60-64. doi:10.1097/01.sap.0000112284.55095.05
  14. ↑ Lin BJ, Chen KT, Jung SM. Endoscopic transorbital approach for orbital apex and superior orbital fissure lesions: technical note and case series. World Neurosurg. 2024;181:e520-e528. doi:10.1016/j.wneu.2023.10.089
  15. ↑ 15.0 15.1 15.2 15.3 Jeon JS, Kim SD, Kwon HJ, et al. Clinical course and prognostic factors in patients with traumatic superior orbital fissure syndrome. Br J Oral Maxillofac Surg. 2019;57(10):1055-1060. doi:10.1016/j.bjoms.2019.09.019

External Links

Retrieved from "http://otowiki.org/index.php?title=Superior_Orbital_Fissure_Syndrome&oldid=356"